Tandem (TNDM) stock falls and Insulet (PODD) stock gains as investors react to the companies' Q2 2025 results and guidance.

Tandem Diabetes reports record Q2 2025 sales, progressing toward $1B goal. Learn about product advances, pharmacy expansion, and international growth.

Tandem Diabetes Care issued a voluntary correction for an insulin pump model due to a speaker malfunction that disrupts communication with glucose monitoring systems, potentially causing high blood ...

Tandem Diabetes Care ( (TNDM) ) has released its Q2 earnings. Here is a breakdown of the information Tandem Diabetes Care presented to its investors.Elevate Your Investing Strategy: Take advantage of ...